When Seres Therapeutics reported positive late-stage data for its experimental microbiome treatment last month, scientists at Finch Therapeutics cheered the results from the rival company whose lead drug candidate addresses the same gut infection they aim to treat.
Positive data, no matter the source, helps the entire microbiome therapies field and paves the way for discussions with regulators, says Finch CEO Mark Smith. He adds that the data also help discussions with investors. Finch announced Thursday that it has raised $90 million to support its entire pipeline of microbiome therapies.
“It helps us in a lot of ways,” Smith says of... Read more »
UNDERWRITERS AND PARTNERS
Author: Frank Vinluan
Date : 2020-09-17T11:00:49.000Z